Navigation Links
Cytokinetics to Present at the 14th Annual Needham Healthcare Conference
Date:4/8/2015

South San Francisco, CA (PRWEB) April 08, 2015

CYTOKINETICS TO PRESENT AT THE 14TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 11:20 AM at the Westin New York Grand Central in New York, NY.

Interested parties may access the live audio of this presentation by visiting the Investor Relations section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investor Relations section of Cytokinetics' website for two weeks following the completion of the event.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics is developing tirasemtiv, a fast skeletal muscle activator, as a potential treatment for amyotrophic lateral sclerosis (ALS). Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at http://www.cytokinetics.com/.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics’ drug candidates and potential drug candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

Contacts:
Cytokinetics, Incorporated:                        
Joanna L. Goldstein    
Manager, Investor Relations & Corporate Communications
(650) 624-3000

Read the full story at http://www.prweb.com/releases/2015/04/prweb12640730.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis
2. Cytokinetics Announces Completion of Enrollment in COSMIC-HF
3. Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 14TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
5. BioSpecifics Technologies Corp. to Present at the 14th Annual Needham Healthcare Conference
6. Immunocore to Present IMCgp100 Clinical Trial Data at AACR Annual Meeting 2015
7. Echo Labs Selects PMBC Group to Represent Biowearable Blood Monitoring Device
8. KaloBios to Present at the 14th Annual Needham Healthcare Conference
9. Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015
10. Synthetic Biologics SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015
11. Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... Ariz. (PRWEB) , ... June 22, 2020 , ... ... is now offering an Amniosomes special offer. This includes buy three, get the ... should call (888) 568-6909. , Amniotic derived exosomes, known as exosomes, have been ...
(Date:6/19/2020)... Russia (PRWEB) , ... June 18, 2020 , ... The ... 2018. Its goal is to join forces to radically prolong life and find a ... postpone the aging period. This project was supported by various scientists from all over ...
(Date:6/11/2020)... ... June 09, 2020 , ... TRX Systems, developer of ... Solution, a highly accurate, contact tracing solution for identification of employees who ... a core disease control measure, is a key strategy for preventing further spread ...
(Date:6/2/2020)... ... 2020 , ... As part of its ongoing mission to ... enterprise security solutions provider bitsIO donated time to help two companies improve operations ... and shelter-in-place orders, companies are increasingly concerned about the security of their networks. ...
Breaking Biology Technology:
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
(Date:6/23/2020)... ... June 23, 2020 , ... In its June 22 online post, business and ... L. Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company Asymmetrex ... 16 that starting July 5 it would begin offering free tissue stem ...
(Date:6/11/2020)... ... June 08, 2020 , ... Cryo-Cell International’s announcement ... to protect workers in the medical field. The face masks will be distributed ... their lives every day to provide healthcare to pregnant women. The delivery of ...
Breaking Biology News(10 mins):